Trial Profile
A Multicenter, Randomized, Single-blind, Placebo-Controlled, Parallel Assignment Study to Evaluate the Efficacy and Safety of Nafamostat Combined with Favipiravir For the Treatment of COVID-19
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Mar 2023
Price :
$35
*
At a glance
- Drugs Favipiravir (Primary) ; Nafamostat (Primary) ; Tocilizumab
- Indications COVID-19 pneumonia
- Focus Therapeutic Use
- 01 Mar 2023 Status changed from recruiting to completed.
- 01 Mar 2023 Results assessing efficacy and safety of nafamostat combined with favipiravir for the treatment of COVID-19, published in the International Journal of Infectious Diseases.
- 01 Mar 2023 Primary endpoint (The change in patient condition according to the WHO clinical progression scale) has not been met.